Waregem (Belgium) / Rotterdam (Netherlands)[1], 12 November 2010 – EnHold NV, the entity with which Waterland Private Equity Fund IV CV participates in Arseus NV, has informed Arseus NV that the mandate of Socius BVBA, represented by Mr Marcel Colla, as the permanent representative of EnHold NV in the Arseus NV Board of Directors, will be terminated as from 13 November 2010. EnHold NV has informed Arseus NV that it will be appointing De Wilde J Management BVBA, represented by Mr Julien De Wilde, as the permanent representative of EnHold NV, on 13 November 2010. Therefore, De Wilde J Management BVBA, represented by Mr Julien De Wilde, will from that day be the permanent representative of EnHold NV, a member of the Arseus NV Board of Directors.
Robert Peek, Chairman of the Arseus NV Board of Directors: “In recent years, Arseus has concentrated on its internal organisation and acquisitions in Europe. With the acquisition of the American company Gallipot in May this year, Fagron has taken its first step as a global consolidator in the niche market of pharmaceutical compounding. Potential acquisition opportunities are currently being sought for Fagron in Scandinavia, Central and Eastern Europe, the United States, Canada and Latin America.
The further expansion of Arseus’ international activities requires a different combination of experiences on the Board of Directors. Mr De Wilde’s management qualities and extensive international experience make him ideally suited to play an important part in the further international development of Arseus from the Board of Directors.
On behalf of the other members of the Board of Directors, I would like to thank Mr Marcel Colla for his involvement and constructive contribution to the work of the Board of Directors.”
[1] This press release was sent out by Arseus NV and Arseus BV.